Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre (ID: 60014618), Cairo, Egypt.
Pharmacology Department, Medical Research and Clinical Studies Institute, National Research Centre (ID: 60014618), Cairo, Egypt.
Life Sci. 2023 Mar 1;316:121405. doi: 10.1016/j.lfs.2023.121405. Epub 2023 Jan 18.
Osteoarthritis (OA) is a multifactorial degenerative disease marked by the progressive deterioration of articular cartilage with inflammation of the synovium. OA's main symptoms include pain and function loss. Monosodium Iodoacetate (MIA) experimental model is widely-used for OS induction since it produces symptoms comparable to those occurring in humans.
Thirty-two rats were divided into four groups (n = 8). The 1st group received saline and included the normal-control rats. Groups 2-4 received intra-articular injections of MIA (3 mg/50 μL) in the rats' knee joints to induce OA. Group 2 included the MIA-control rats. Groups 3 and 4 received intra-articular MIA followed by a 14-day oral eplerenone (50 and 100 mg/kg); respectively.
Intra-articular injection of MIA in rats' knee joints caused significant inflammation and pain, elevation of Akt and ERK gene expression in knee joints along with significant alterations in the histological pictures of knee joints and OARSI scores. RANKL/OPG Axis was significantly disrupted.
Eplerenone treatment produced a significant improvement in motor coordination and spontaneous locomotor activity in rats and modulated the key inflammatory mediators in OA (TNF-α, NF-κβ, and IL-6). Eplerenone also suppressed the qRT-PCR gene expression of Akt and ERK in knee joint tissues and improved the histological pictures and OARSI scores of knee joints of treated rats. Eplerenone caused a decline in RANKL concentration accompanied by a rise in OPG concentration thus modulating the RANKL/OPG Axis. Consequently, eplerenone is a candidate for OA therapy due to its potential anti-inflammatory effects.
骨关节炎(OA)是一种多因素退行性疾病,其特征是关节软骨进行性恶化,滑膜炎症。OA 的主要症状包括疼痛和功能丧失。碘乙酸单钠(MIA)实验模型因其可产生类似于人类发生的症状而被广泛用于 OS 诱导。
将 32 只大鼠分为 4 组(n = 8)。第 1 组给予生理盐水,包括正常对照组大鼠。第 2-4 组大鼠膝关节内注射 MIA(3 mg/50 μL)以诱导 OA。第 2 组为 MIA 对照组。第 3 组和第 4 组在膝关节内注射 MIA 后分别给予 14 天口服依普利酮(50 和 100 mg/kg)。
向大鼠膝关节内注射 MIA 可引起明显的炎症和疼痛,Akt 和 ERK 基因在膝关节中的表达升高,膝关节的组织学图片和 OARSI 评分发生显著改变。RANKL/OPG 轴显著中断。
依普利酮治疗可显著改善大鼠的运动协调和自发运动活动,并调节 OA 的关键炎症介质(TNF-α、NF-κβ 和 IL-6)。依普利酮还抑制了关节组织中 Akt 和 ERK 的 qRT-PCR 基因表达,并改善了治疗大鼠膝关节的组织学图片和 OARSI 评分。依普利酮可降低 RANKL 浓度,同时增加 OPG 浓度,从而调节 RANKL/OPG 轴。因此,依普利酮因其潜在的抗炎作用而成为 OA 治疗的候选药物。